A combination of durvalumab and standard first-line chemotherapy has shown promise for the management of untreated patients with advanced mesothelioma unsuitable for surgery. The phase 2 single-arm Australian study, published in The Lancet Oncology, is the first clinical trial reporting on the combination of a checkpoint inhibitor and standard chemotherapy in malignant pleural mesothelioma. The ...
Durvalumab promises boost over chemo in mesothelioma: DREAM study
By Mardi Chapman
9 Sep 2020